ArticleFrontiers in oncology2022

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients.

Emeline Orillard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.